iBIO https://ibio.org To promote, connect and engage the life sciences community Mon, 18 Nov 2019 18:06:24 -0600 en-US hourly 1 https://ibio.org/wp-content/uploads/cropped-android-chrome-512x512-32x32.png iBIO https://ibio.org 32 32 #ThisShirt Sends a Girl to STEMgirls CAMP https://ibio.org/thisshirt-sends-a-girl-to-stemgirls-camp/ https://ibio.org/thisshirt-sends-a-girl-to-stemgirls-camp/#respond Mon, 18 Nov 2019 15:17:57 +0000 https://ibio.org/?p=4588

This Giving Tuesday please commit to helping girls grades 3-8 discover and embrace their interests, self-confidence and skills in STEM by purchasing our t-shirts.

Every t-shirt we sell helps a girl from an underserved Illinois community attend our STEMgirls Camp (25 shirts = 1 camper), which empowers girls to explore STEM through fun, hands-on STEM and STEAM-centered activities.

Since 2011 our programming has helped over 2,100 girls develop a belief in their own abilities and make connections between the hands-on explorations and future careers in the STEM field. 

There is only a limited time to purchase. This campaign ends the day after Giving Tuesday on December 4, 2019!

Help us send a girl to camp and share online why its important for you that #ThisShirt inspires a future scientist.

https://ibio.org/thisshirt-sends-a-girl-to-stemgirls-camp/feed/ 0
Endotronix Announces Positive Data from the SIRONA First-in-Human Trial for the Cordella™ PA Pressure Sensor System https://ibio.org/endotronix-announces-positive-data-from-the-sirona-first-in-human-trial-for-the-cordella-pa-pressure-sensor-system/ https://ibio.org/endotronix-announces-positive-data-from-the-sirona-first-in-human-trial-for-the-cordella-pa-pressure-sensor-system/#respond Mon, 18 Nov 2019 13:58:13 +0000 https://ibio.org/?p=4611 Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), presented positive first-in-human data of the Cordella™ Pulmonary Artery (PA) Pressure Sensor System (Cordella Sensor). Data was presented at the 2019 American Heart Association (AHA) Scientific Sessions in Philadelphia, PA by Prof. Dr. Wilfried Mullens of the Hospital Oost-Limburg in Genk, Belgium.

“Chronic heart failure patients too frequently have cycles of decompensation and hospitalization that negatively impact patient outcomes and drive up treatment costs. Recent data shows that using PA pressure-guided therapy with this population keeps them healthier and out of the hospital,” stated Prof. Dr. Mullens. “The Cordella System is an elegant solution that integrates a PA pressure sensor and a comprehensive patient management platform in one. The straightforward sensor implant provides reliable pressure data, while the patient management platform enables a comprehensive clinical picture of the patient that allows my team to make informed therapy decisions and improve outcomes.”

The 90-day results from the first-in-human trial confirm the device safety and accuracy of pressure measurements in the right pulmonary artery using the implanted Cordella Sensor and handheld patient reader. The study included 15 patients across two European sites: Prof. Dr. Mullens in Belgium and Dr. Faisal Sharif of the National University of Ireland(NUI) in Galway, Ireland.

Highlights include:

  • The primary accuracy endpoint was met with no significant difference in measured mean PA pressure for the Cordella Sensor and the reference catheter at 90 days.
  • The study demonstrated encouraging safety results with zero Device Related System Complications (DSRC) at 90 days.
  • High patient compliance (>98%) with daily remote measurements of vital signs and PA pressure throughout the study.

“The presentation of our first-in-human data at AHA this year is another exciting milestone for the company,” commented Dr. Katrin Leadley, Chief Medical Officer of Endotronix. “This work lays the clinical foundation for our groundbreaking IDE trial, PROACTIVE-HF, which will begin enrollment in the U.S. later this year. Designed to provide the highest level of clinical evidence for PA pressure-guided therapy, PROACTIVE-HF will support U.S. market access of the Cordella Sensor and inform a national coverage decision from the Centers for Medicare & Medicaid Services (CMS).”

The Cordella Sensor is not available for commercial use in any geography and is under clinical investigation in Europe(SIRONA II CE Mark Trial) and the U.S. (PROACTIVE-HF IDE Trial). CAUTION – Investigational Device. Limited by Federal (or United States) Law to Investigational Use. Exclusively for clinical investigations. The Cordella System, without the sensor, is available for commercial use in the U.S. and E.U. and is currently in cardiology centers across the U.S.

About the Cordella™ Heart Failure System
The Cordella Heart Failure System (Cordella System) is designed to help patients suffering from chronic heart failure feel better and stay out of the hospital with streamlined care and remote medication titration. The system provides a comprehensive health status of the patient at home with easy-to-use tools to securely collect and share health related data with healthcare providers for trend-based management. The Cordella Sensor seamlessly integrates pulmonary artery (PA) pressure data into the Cordella System. Together, they proactively deliver the information necessary to improve patient care between office visits and support reimbursement for care delivery activities.

About Endotronix
Endotronix, Inc., is a medical technology company focused on advancing the treatment of chronic heart failure. Privately held, the company is backed by world-class medtech investors including Aperture Venture Partners, BioVentures Investors, LSP, Lumira Ventures, OSF Ventures, Seroba Life Sciences, Skydeck LLC, SV Health Investors, Wanxiang Healthcare Investments, and two unnamed corporate strategic investors. Learn more at www.endotronix.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not a guarantee of future performance.

Carla Benigni
SPRIG Consulting LLC (847) 951-7430

https://ibio.org/endotronix-announces-positive-data-from-the-sirona-first-in-human-trial-for-the-cordella-pa-pressure-sensor-system/feed/ 0
Actuate Therapeutics Inc. Completes $6.5 Million Series B-3 Financing https://ibio.org/actuate-therapeutics-inc-completes-6-5-million-series-b-3-financing/ https://ibio.org/actuate-therapeutics-inc-completes-6-5-million-series-b-3-financing/#respond Fri, 15 Nov 2019 19:14:57 +0000 https://ibio.org/?p=4609 Actuate Therapeutics, Inc. has raised an additional $6.5M in a Series B-3 financing round led by Bios Partners with Kairos Ventures, DEFTA Partners, and other existing investors participating. This Series B-3 brings total funding for Actuate’s Series B round to over $28.2M.

Actuate is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutic agents for patients with cancer or inflammatory diseases. Actuate will use the proceeds of the financing to initiate a Phase 2 clinical trial in myelofibrosis and expand the company’s ongoing 1801 clinical trial to include an arm for treating patients with a combination of 9-ING-41 with irinotecan.

“Myelofibrosis is a therapeutically challenging myeloproliferative neoplasm where we need novel approaches and where recent findings support the potential clinical benefits of anti-fibrotic therapy. 9-ING-41 has demonstrated significant activity in reversing pathologic fibrosis with attendant restoration of normal function in pre-clinical models of fibrotic diseases. In addition, 9-ING-41 has significant anti-neoplastic activity and is without clinically significant adverse events to date,” said Dr. Frank Giles, Actuate’s Chief Medical Officer. “The absence of myelosuppression with 9-ING-41 is particularly important for patients with advanced myelofibrosis for whom we are initiating the international Phase 2 study of 9-ING-41 as a single agent and in combination with ruxolitinib, the current standard of care for treatment of myelofibrosis.”

The 1801 clinical trial was designed as a histology agnostic study with seamless extension from the investigation of single agent therapy to that of six different 9-ING-41-based combinations with standard-of-care chemotherapeutics. The initial combinations were prioritized based on evidence of reversal of resistance to key cytotoxic agents in diverse pre-clinical models. The design has proven to be efficient and highly productive, with over 70 patients enrolled since the start of the study in January.

“Key data from the 1801 study on the pharmacokinetics of, tolerability of, and clinical responses to 9-ING-41 have been very rapidly developed in the context of vigorous accrual by our investigators,” said Dr. Ludimila Cavalcante, Actuate’s Lead, Medical Affairs. “Adding irinotecan as a partner agent to 9-ING-41 will significantly expand the options we can offer patients being treated on the 1801 study, particularly those with advanced gastrointestinal cancers. Data on adults receiving 9-ING-41 combined with irinotecan will also inform the optimal design of our planned studies in children and adolescents with neuroblastoma.”

“We are very pleased with the progress we are making in the clinic with the 1801 study, and the promise of the myelofibrosis and neuroblastoma trials which we expect to initiate early in 2020,” said Daniel Schmitt, President and CEO of Actuate. “We are also pleased with the ongoing support of our investors in the Series B financing, which allows us to continue this important and promising work.”

https://ibio.org/actuate-therapeutics-inc-completes-6-5-million-series-b-3-financing/feed/ 0
Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders https://ibio.org/exicure-and-allergan-enter-into-collaboration-option-and-license-agreement-to-discover-and-develop-sna-based-treatments-for-hair-loss-disorders/ https://ibio.org/exicure-and-allergan-enter-into-collaboration-option-and-license-agreement-to-discover-and-develop-sna-based-treatments-for-hair-loss-disorders/#respond Fri, 15 Nov 2019 19:13:20 +0000 https://ibio.org/?p=4607 Exicure to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones

CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc., (NASDAQ:XCUR) a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Exicure, Inc. have entered into a global collaboration agreement to discover and develop novel treatments for hair loss disorders based on Exicure’s proprietary SNA technology.

Under the terms of the agreement, Allergan will receive exclusive access and options to license SNA-based therapeutics arising from two collaboration programs related to the treatment of hair loss disorders. Exicure will receive an upfront payment of $25 million and will conduct discovery and development in two collaboration programs for hair loss disorders. In the event that Allergan exercises an option, Allergan will be responsible for clinical development and commercialization of the licensed products. Exicure will be eligible to receive development and regulatory milestones of up to $97.5 million per program and commercial milestones of up to $265 million per program. Exicure will also be eligible to receive tiered royalties on worldwide net product sales of mid-single digit to mid-teens percentages on worldwide net product sales.

“We are excited to combine our knowledge of nucleic acid therapeutics with Allergan’s deep expertise in medical aesthetics to develop and commercialize innovative treatments for hair loss disorders.” said Dr. David Giljohann, chief executive officer of Exicure. “This collaboration is an exciting opportunity to advance Exicure’s SNA technology in an important new therapeutic area.”

Additional Details about the Collaboration and Hair Loss Program

One of the most common hair loss disorders and a subject of the collaboration is androgenetic alopecia also known as pattern baldness, affecting approximately 50 million men and 30 million women in the United States. It is estimated that over $3.5 billion a year is spent on treatments, the majority of which are ineffective.

Conference Call Today at 8:30am ET/7:30am CT

Exicure will hold a conference call at 8:30am ET to provide a corporate update and to discuss the strategic collaboration announced today. A live audio only webcast of the conference call can be accessed in the Investors section of the company’s website at www.exicuretx.com. To participate in the conference call, please dial 866-997-1948 or 270-215-9856 five minutes prior to start time. The conference ID is 9849047. An archived version of the webcast will be available on Exicure’s website for 30 days.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.Allergan.com.

About Exicure

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure’s lead program is in a Phase 1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and in Cambridge, MA.

For more information, visit Exicure’s website at www.exicuretx.com.

Exicure Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company, the Company’s technology, potential therapies, cash requirements and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: unexpected costs, charges or expenses that reduce cash runway; that Exicure’s pre-clinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; that many drug candidates that have completed Phase 1 trials do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; and the ability of Exicure to protect its intellectual property rights. Risks facing the Company and its programs are set forth in the Company’s filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement (including without limitation its cash runway guidance) or to make any other forward-looking statements, whether as a result of new information, future events or otherwise


Stern Investor Relations
Kerry Conlin

Karen Sharma

https://ibio.org/exicure-and-allergan-enter-into-collaboration-option-and-license-agreement-to-discover-and-develop-sna-based-treatments-for-hair-loss-disorders/feed/ 0
MedTech Innovator Now Accepting Applications for 2020 Program https://ibio.org/medtech-innovator-now-accepting-applications-for-2020-program/ https://ibio.org/medtech-innovator-now-accepting-applications-for-2020-program/#respond Fri, 15 Nov 2019 19:04:58 +0000 https://ibio.org/?p=4602 Applications are now being accepted for MedTech Innovator 2020. This is a unique opportunity for start-ups and emerging growth medical technology companies to gain access to industry stakeholders such as Baxter, BTG, HOYA, Maxim Ventures, Johnson & Johnson, Olympus, NIPRO, W.L. Gore and RCT Ventures.

The top 50 start-ups selected each receive complimentary registration and are featured in the MedTech Innovator Showcase at The MedTech Conference, taking place October 5-7, 2020 in Toronto. MedTech Innovator will award up to $500,000 in non-dilutive cash prizes and in-kind awards during the 2020 competition.

The grand prize winner will be announced during the MedTech Innovator Finals at The MedTech Conference. The final deadline for applications is Jan. 17, 2020. Early entry is recommended for priority reviews.

Apply Now

https://ibio.org/medtech-innovator-now-accepting-applications-for-2020-program/feed/ 0
Illinois Needs to Protect Patient’s Access to Sterilized Medical Equipment https://ibio.org/illinois-needs-to-protect-patients-access-to-sterilized-medical-equipment/ https://ibio.org/illinois-needs-to-protect-patients-access-to-sterilized-medical-equipment/#respond Wed, 13 Nov 2019 13:29:43 +0000 https://ibio.org/?p=4586 On November 1, 2019 Crain’s Chicago Business published an op-ed “It’s time for Illinois to protect residents from this cancer-causing agent” by Nancy C. Loeb.

Ms. Loeb’s misleading op-ed included a number of  misstatements on the use of Ethylene Oxide (EO) for medical device sterilization that need to be corrected.

In her op-ed, Ms. Loeb states “there are several other methods for sterilizing medical equipment”, and provides a link to a FDA Sterilization Guidance document. But this claim and the link to the FDA is misleading. The FDA clearly addresses the possibility of alternative sterilization methods in an October 25th statement from FDA Acting Commissioner Norman Sharpless:

“It’s important to note at this time there are no readily available processes or facilities that can serve as viable alternatives to those that use ethylene oxide to sterilize these devices. In short: this method is critical to our health care system and to the continued availability of safe, effective and high-quality medical devices.”

In addition, the concern about trace ethylene oxide from these plants is misguided and unsupported by science. EO sterilization plants go above and beyond federal law, using the best available technology to destroy and abate EO emissions. Toxicologists confirm that the air around these plants poses no threat to public health whatsoever.

This summer Governor Pritzker signed into law the most restrictive limits on Ethylene Oxide emissions, requiring companies to install the most advanced pollution control equipment available.

Despite passing this legislation, Illinois lawmakers are considering additional legislation (HB 3888 and SB 0557) that could effectively close the remaining EO sterilization facilities in Metro-Chicago which may quickly lead to real harm for Illinois patients and patients throughout the Midwest.

The FDA’s October 25th statement alerts the public and policy makers about the FDA’s growing concerns about the future availability of sterile medical devices and impending medal devise shortages related to the closure of facilities in Illinois and Georgia.

Without adequate availability of EO sterilization facilities, the FDA anticipates national shortages of surgical kits used in emergency and routine procedures along with other critical devices including feeding tubes used in neonatal intensive care units, drug-elating cardiac stents, catheters, shunts and other implantable devices. This statement and the potential impact of passing legislation that could close these facilities was not included in Ms. Loeb’s op-ed.

Illinois already passed legislation this year to address emissions from EO sterilization facilities and the chemical is fundamentally safe at very low levels of exposure which occur every day from a variety of other sources.

Additional legislation is not needed, and it could pose a real threat to Hospitals and patients in Illinois.

https://ibio.org/illinois-needs-to-protect-patients-access-to-sterilized-medical-equipment/feed/ 0
Headed to #JPM20? iBIO Members get free access to BIO’s 1X1 Partnering System and Discounted Meeting Space https://ibio.org/headed-to-jpm20-ibio-members-get-free-access-to-bios-1x1-partnering-system-and-discounted-meeting-space/ https://ibio.org/headed-to-jpm20-ibio-members-get-free-access-to-bios-1x1-partnering-system-and-discounted-meeting-space/#respond Tue, 12 Nov 2019 14:53:06 +0000 https://ibio.org/?p=4583 Real estate in San Francisco is expensive, and its next to impossible January 13th – 16th during the JP Morgan Healthcare Conference.

iBIO Members can connect with companies, investors, in-licensors and others using BIO’s partnering system, which is available to you regardless of whether you are attending any particular conference during JPM week. IBIO Members can schedule meetings in your own meeting space or in public space for free. You can also schedule meetings in BIO’s prime meeting space at the San Francisco Marriott Marquis (4th & Mission) at competitive rates using BIO’s partnering system.


https://ibio.org/headed-to-jpm20-ibio-members-get-free-access-to-bios-1x1-partnering-system-and-discounted-meeting-space/feed/ 0
Cyclopure Named to C&EN’s 10 Start-UPS to Watch https://ibio.org/cyclopure-named-to-cens-10-start-ups-to-watch/ https://ibio.org/cyclopure-named-to-cens-10-start-ups-to-watch/#respond Mon, 11 Nov 2019 13:07:20 +0000 https://ibio.org/?p=4579 Cyclopure based out of the Illinois Science + Technology Park in Skokie, Illinois was named in C&EN’s annual list of startups to watch.

CycloPure is a materials science company and a leader in water purification technologies.  The company’s line of DEXSORB adsorbents are based on breakthrough technology that converts renewable, corn-based cyclodextrins into highly adsorbent materials engineered to safely strip away hundreds of micropollutants, including perfluorinated compounds (PFOA and PFOS), pesticides, and pharmaceutical compounds from drinking water.

In September Cyclopure announced a $1 million SBIR Phase II grant.

Click here to read C&EN’s 10 Star-ups to Watch


https://ibio.org/cyclopure-named-to-cens-10-start-ups-to-watch/feed/ 0
Now Is the Time to Prepare Your NCATS Small Business Funding Applications https://ibio.org/now-is-the-time-to-prepare-your-ncats-small-business-funding-applications/ https://ibio.org/now-is-the-time-to-prepare-your-ncats-small-business-funding-applications/#respond Fri, 25 Oct 2019 01:57:55 +0000 https://ibio.org/?p=4418 Omnibus Solicitation application deadline: Jan. 6, 2020, 5:00 p.m. local time  
Are you thinking about applying for small business funding this year? Now is the time to start your submission for the Jan. 6, 2020 deadline. The National Center for Advancing Translational Sciences (NCATS) has funding opportunities open for small business biotech entrepreneurs and researchers under the  Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.
2019 Omnibus Grant Solicitation: due Jan. 6, 2020

Small businesses and research organizations involved in commercializing innovative medical technologies are encouraged to apply for the 2019 Omnibus Grant Solicitations (SBIR: PA-19-272) and STTR:  PA-19-270). If you have your application almost ready, be sure to submit by the Monday,Jan. 6, 2020 deadline. The next deadline will be Apr. 6, 2020. NCATS is particularly interested in applications that address research areas relevant to any stage of translation, from target validation through pre-clinical and clinical evaluation, to intervention implementation and dissemination, including:

SBIR and STTR applicants can apply for Phase I and Phase II funding. SBIR applicants can also now opt to apply for Direct-to-Phase II Funding.  This award allows small businesses to submit Direct-to-Phase II SBIR applications if the small business has performed the Phase I stage-type research through other funding sourcesAn updated SBIR/STTR Application Guide with additional instructions for the newly reinstated SBIR Direct Phase II application preparation and submission is now available.

Questions? NCATS encourages applicants to email NCATS-SBIRSTTR@mail.nih.gov to discuss potential project ideas and related questions.

Why Apply?

  • Funding is stable, predictable and not a loan
  • Capital is non-dilutive
  • Small businesses and research organizations retain intellectual property rights
  • NIH’s rigorous peer-review provides recognition, validation and visibility to early-stage companies
  • Prestige associated with these awards can help attract more funding or other support (e.g., venture capital, strategic partners)

Tips for Applying:

  1. Clear all administrative requirements: Applicants must meet all eligibility requirements and must complete all required registrations prior to submission. Register your small business with Grants.govSAM.gov, the NIH eRA Commons and the SBA Company Registry (NEW)  as soon as possible. Principal Investigators must also individually register with NIH eRA Commons. Those eligible to certify as a Women-Owned Small Business (WOSB) should obtain the WOSB designation, and those eligible to certify as a Minority-Owned Small Business should obtain certification.
  2. Build and submit a strong application: Follow the SBIR/STTR Application Guide to ensure proper grant application content and format. You can also find examples of successful applications on a variety of topics on the NIH website.
  3. Submit before the deadline: Completing all the required steps can take a month or two, so don’t wait until the last minute: Plan ahead to help ensure your application moves forward for consideration successfully.
https://ibio.org/now-is-the-time-to-prepare-your-ncats-small-business-funding-applications/feed/ 0
House Democrats’ Drug Pricing Plan Would Be Bad Medicine for Governor Pritzker’s Economic Plan for Illinois https://ibio.org/house-democrats-drug-pricing-plan-would-be-bad-medicine-for-governor-pritzkers-economic-plan-for-illinois/ Thu, 24 Oct 2019 11:22:08 +0000 https://ibio.org/?p=4414 On October 9th Governor Pritzker identified the life sciences industry as a key economic pillar in the Illinois Department of Commerce and Economic Opportunity’s (DCEO) five-year plan to revitalize the Illinois economy and build the workforce of the future. This was great news for our industry in Illinois, but the Governor’s plan is already at risk.

The U.S. House Democrats’ Drug Pricing Proposal (H.R.3), introduced by Speaker Nancy Pelosi, includes a number of far-reaching and misguided policies, including imposing price setting and access-restricting polices for patients, would destabilize incentives and chill R&D investment in the biopharma industry in Illinois.

If implemented H.R.3 would give the government unprecedented authority to set wholesale prices for medicine in public and private markets based on the average sales price from other countries. Companies who do not comply or participate in the negotiations will be charged an excise tax of up to 95% of the gross sales for the medicine. The nonpartisan Congressional Budget Office (CBO) completed a preliminary analysis of H.R. 3 and concluded that over 10 years the biopharma industry would lose between $500 billion and $1 trillion in revenue, and would result in a loss of eight to 15 new drugs over the decade.

According to a Ernst & Young study, the biopharma industry and its more than 45,000 employees contributes more than $1 billion in state and local taxes in Illinois. The biopharma industry industry runs on profit margins of 10% to 20%, meaning there’s not much room to cut revenues. Based on these CBO estimates, companies will need to cut operations including R&D. These cuts could cripple the industry in Illinois, including a potentially drastic reduction in the number of researchers, doctors, lawyers, and business women and men employed by the biopharma industry in Illinois. Our state can not afford the economic impact of a significant loss in jobs, not after the employment reductions we’ve experienced due to a migration of companies to the coasts.

Even more concerning are the ancillary impacts price setting will have on the startup biopharma companies who account for over 70% of the global clinical pipeline. By restricting returns on investment, H.R.3 would greatly destabilize the venture capital community, which is very sensitive to policy changes that would affect the price-innovation trade-off. And price restrictions resulting in cutting R&D budgets would endanger any public-private research projects and partnerships the state intends to build with the Discovery Partners Institute (DPI) in Chicago.

Finally and most importantly, H.R.3 would create barriers to patients accessing the medications they need. A key provision of H.R.3 would tie U.S. drug prices to those paid by Japan and several European, single-payer health care systems whose restrictive policies offer fewer innovative medicines to their citizens. By comparison, nearly 90% of new medicines launched from 2011 to 2018 are available in the U.S., but just 64% are available in Germany, 59% in the U.K., 51% in Japan, 50% in France, and 46% in Canada. And setting U.S. prices to the countries listed above would tie U.S. to flawed price setting schemes, like Quality Adjusted Life Years, that are clinically flawed and prejudicial to patients viewed as providing less economic benefit like the elderly, disabled and rare disease populations.

Yes, it is critical that policy makers address out-of-pocket costs for patients, but legislation should be designed with the understanding that ambiguity raises the costs of drug development and decreases investment in future innovation. Policies should focus on commonsense reforms, like sharing negotiated rebate savings with patients at the pharmacy counter, promoting value-based payment by removing barriers that limit value-based contracting arrangements and lowering out-of-pocket costs in Medicare.

The three committees with jurisdiction over H.R.3 are moving forward quickly, all having held markups. Democratic leaders are setting an aggressive timeline for action with the hope of having the legislation potentially pass the House floor by the end of October.

What can you do? Reach out directly to your Members of Congress to urge them to OPPOSE H.R. 3 by going to: www.savecures.org.

iBIO is committed to working with our partners to address these critical issues, but as it stands today,  H.R.3 is bad for patients and the Illinois economy.

More Information: